Form 4: Context Therapeutics Director Andy Pasternak Granted Significant Stock Options

Context Therapeutics Inc. director Andy Pasternak was granted 138,900 stock options with an exercise price of $0.653, aligning his interests with shareholder value.

Summary

• Andy Pasternak, a Director of Context Therapeutics Inc. (CNTX), was granted 138,900 stock options.
• The transaction date for this grant was June 12, 2025.
• The exercise price for these stock options is $0.653 per share.
• The options will vest and become exercisable on the earlier of June 12, 2026 (the one-year anniversary of the grant date) or the Issuer's 2026 annual meeting of stockholders.
• Vesting is subject to Mr. Pasternak's continued service with Context Therapeutics Inc.
• The expiration date for these stock options is June 11, 2035.
• Following this transaction, Mr. Pasternak directly beneficially owns 138,900 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine disclosure, the grant of options aligns the director's interests with the company's long-term performance, which is generally viewed favorably by investors as it incentivizes value creation.

Positives

• The grant of stock options to a director aligns management's and the board's interests with those of shareholders, incentivizing long-term value creation.
• Equity compensation is a common and effective way to attract and retain experienced directors.

Future Outlook

The vesting schedule of the stock options, contingent on continued service, indicates an expectation of Andy Pasternak's ongoing involvement and contribution as a director of Context Therapeutics Inc. through at least mid-2026.

Industry Context

The granting of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, particularly for companies like Context Therapeutics Inc. which are often in development stages. This form of compensation is used to conserve cash while incentivizing long-term performance and aligning director interests with shareholder returns.

Comparison to Industry Standards

• The practice of granting stock options as part of director compensation is a widely accepted standard across various industries, including biotechnology, to align the interests of directors with long-term shareholder value.
• While the specific number of options and exercise price are unique to this grant, the structure (vesting over time, subject to continued service) is typical for equity compensation plans for board members.
• This document does not provide specific comparable companies, projects, or results to benchmark the size or terms of this particular grant against direct peers, but the mechanism itself is standard.

Related Party Transactions

• The grant of stock options to Andy Pasternak, a Director of Context Therapeutics Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with the company's stock performance, potentially leading to decisions that enhance shareholder value.
• Employees: While not directly impacting general employees, such compensation practices can set precedents for executive and board remuneration structures within the company.

Next Steps

• The stock options will vest on the earlier of June 12, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• Upon vesting, Andy Pasternak will have the right to exercise these options to acquire common stock of Context Therapeutics Inc. at the specified exercise price.

Key Dates

Recommendation

Keywords

Context Therapeutics, CNTX, Stock Option, Director Compensation, Equity Grant, SEC Form 4, Beneficial Ownership